Clene Inc. (CLNNW)
0.03
-0.02 (-40.00%)
At close: Jan 15, 2025, 3:21 PM
0.03
-2.65%
After-hours Jan 15, 2025, 03:22 PM EST
undefined% (undefined)
| Bid | 0.03 |
| Market Cap | 37.97M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.05 |
| Volume | 58,862 |
| Avg. Volume (20D) | 0 |
| Open | 0.04 |
| Previous Close | 0.05 |
| Day's Range | 0.03 - 0.04 |
| 52-Week Range | 0.03 - 0.04 |
| Beta | undefined |
About CLNNW
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; com...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 82
Stock Exchange NASDAQ
Ticker Symbol CLNNW
Website https://clene.com